Should intravesical Bacillus Calmette-Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle invasive bladder cancer?
Should intravesical Bacillus Calmette-Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle invasive bladder cancer? — المؤلف: Yuk, Hyeong Dong — PloS one 20190506
- المؤلف
- Yuk, Hyeong Dong
- النشر
- PloS one 20190506
- الوصف
- e0208267 p.
- الموضوعات
- Adjuvants, Immunologic؛ Administration, Intravesical؛ Aged؛ Aged, 80 and over؛ BCG Vaccine؛ Female؛ Humans؛ Male